Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats (Q36731626)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 2012

Language	Label	Description	Also known as
English	Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats	scientific article published on December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats (English)

1 reference

Europe PubMed Central

15 August 2017

0 references

Soluble epoxide hydrolase

0 references

author name string

John D Imig

1

1 reference

Europe PubMed Central

15 August 2017

Katie A Walsh

2

1 reference

Europe PubMed Central

15 August 2017

Md Abdul Hye Khan

3

1 reference

Europe PubMed Central

15 August 2017

Tasuku Nagasawa

4

1 reference

Europe PubMed Central

15 August 2017

Mary Cherian-Shaw

5

1 reference

Europe PubMed Central

15 August 2017

Sean M Shaw

6

1 reference

Europe PubMed Central

15 August 2017

Bruce D Hammock

7

1 reference

Europe PubMed Central

15 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 December 2012

1 reference

Europe PubMed Central

15 August 2017

Experimental Biology and Medicine

1 reference

Europe PubMed Central

15 August 2017

237

1 reference

Europe PubMed Central

15 August 2017

12

1 reference

Europe PubMed Central

15 August 2017

1402-1412

1 reference

Europe PubMed Central

15 August 2017

Epoxides and soluble epoxide hydrolase in cardiovascular physiology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

The safety of thiazolidinediones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Diet-induced obesity impairs endothelium-derived hyperpolarization via altered potassium channel signaling mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

PPARγ and chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Pathogenesis and pathophysiology of the cardiometabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Effects of thiazolidinediones beyond glycaemic control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

K(ATP)-mediated vasodilation is impaired in obese Zucker rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Renal and vascular mechanisms of thiazolidinedione-induced fluid retention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Eicosanoids and renal damage in cardiometabolic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

PPARgamma agonists: safety issues in heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Abdominal obesity and metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Evidence for a potent antiinflammatory effect of rosiglitazone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Peroxisome proliferator-activated receptor γ in diabetes and metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Minireview: Adiposity, Inflammation, and Atherogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Obesity-related glomerulopathy: an emerging epidemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

30 September 2017

Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

28 June 2018

Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Hepatic effects of rosiglitazone in rats with the metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Blockade of endogenous proinflammatory cytokines ameliorates endothelial dysfunction in obese Zucker rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Effect of obesity on inflammatory markers and renal functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Reduced Ca2+-dependent activation of large-conductance Ca2+-activated K+ channels from arteries of Type 2 diabetic Zucker diabetic fatty rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Impaired arachidonic acid-mediated activation of large-conductance Ca2+-activated K+ channels in coronary arterial smooth muscle cells in Zucker Diabetic Fatty rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Peroxisome proliferator-activated receptor gamma in diabetes and metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3613242

5 September 2018

Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The SHROB model of syndrome X: effects of excess dietary sucrose

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/23354399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1258/EBM.2012.012225

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36731626&oldid=2159614450"